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Evidence Based Medicine
High dose Atorvastatin after stroke or Transient Ischaemic
Attack (SPARCL) — Does every stroke patient in Pakistan deserve a statin?
Maria Khan, Ayeesha Kamran Kamal
Stroke Service and Vascular Fellowship Program, Aga Khan University Hospital, Karachi, Pakistan.
Why is this study important? 
It was well established from previous studies that
therapy with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) reduces the risk of stroke
among patients with coronary heart disease and those at
increased risk for cardiovascular disease. But prior to this
study no data existed regarding the benefits of statins in
patients with history of stroke or transient ischemic attacks.
The aim of Stroke Prevention by Aggressive
Reduction in Cholesterol Levels (SPARCL) trial was to
determine the impact of 80 mg of Atorvastatin per day on
stroke prevention in patients with history of stroke or TIA
within the past six months and with no known history of
coronary artery disease. 
Who were the participants?
Patients were eligible if they had a stroke or TIA one
to six months before randomization. Haemorrhagic strokes
were also included if the physicians felt that these patients
were at risk of ischaemic events. Patients with
cardioembolic strokes, subarachnoid haemorrhage,
LDL<100 and modified Rankin score greater than 3 were
excluded. A patient with a Modified Rankin Score of 3 is a
patient with Moderate disability; requiring some help, but
able to walk without assistance
These patients were selected from twenty seven
countries across five continents. Majority of the patients
were from Europe. The contribution from the Middle East
was limited to just 61 patients from Israel. There were no
South Asian patients in this landmark trial.
What was the intervention?
A total of 6670 patients were screened, 4731 were
deemed eligible and were randomly assigned to double-
blind therapy with either 80 mg of Atorvastatin per day or
placebo. 2365 were randomized to active arm and 2366 to
the placebo arm. 
Follow-up visits were scheduled one, three, and six
months after enrollment and every six months thereafter.
Patients were followed up for a median of 4.9 years.
Efficacy and safety analyses were both on intention to
treat basis.
The two groups were well matched in terms of age,
gender, blood pressure, entry event, other risk factors and
concomitant medication use. They were also well matched
with respect to their baseline lipid values.
What was the outcome?
The mean values for LDL, total cholesterol and
triglycerides were significantly lower in the Atorvastatin
arm compared to the placebo arm. Hence treatment was
adhered to. LDL cholesterol was 72.9±0.5 mg per deciliter
in the Atorvastatin group, as compared with 128.5±0.5 mg
per deciliter in the placebo group (P<0.001); total
cholesterol, 147.2±0.6 as compared with 208.4±0.6 mg per
deciliter (P<0.001); and triglycerides, 111.5±1.3 as
compared with 145.0±1.3 mg per deciliter, respectively
(P<0.001). ); high-density lipoprotein (HDL) cholesterol
was 52.1±0.3 in the active arm as compared with 51.0±0.3
mg per deciliter in the placebo arm (P = 0.006).
A primary end point (any nonfatal or fatal stroke)
occurred in 265 patients in the Atorvastatin group and 311
in the placebo group (unadjusted P = 0.05). After
prespecified adjustment for baseline factors, Atorvastatin
was associated with a 16.0 percent relative reduction in the
risk of nonfatal or fatal stroke (hazard ratio, 0.84; 95 percent
confidence interval, 0.71 to 0.99; P = 0.03).
Analysis of secondary end points showed reductions
in the combined risk of stroke and TIA. The risk of
cardiovascular events, including major coronary events and
revascularization procedures, was reduced substantially.
There was however, no significant difference between
treatment groups in overall mortality.
There were significant differences in the treatment
effects based on the type of stroke. The risk was decreased
for ischaemic and unclassified strokes but it was increased
for haemorrhagic strokes with a hazard ratio of 1.66 (95%
CI 1.08-2.55).Persistent elevation of alanine or aspartate
aminotransferase (>3 times the upper limit of the normal
group on two consecutive occasions) was more frequent in
the atorvastatin group (51 patients, or 2.2%) than in the
placebo group (11 patients or 0.5%). There were no cases of
liver failure. 
Safety analysis revealed no significant differences in
the two arms in terms of serious adverse events.
What were the author's conclusions?
The authors concluded that aggressive lowering of
cholesterol in patients with history of prior stroke or TIA
significantly decreases the risk of recurrent non fatal stroke,
major cardiovascular events and need for revascularization.
On the basis of this data, 46 patients (95 percent
confidence interval, 24 to 243) would need to be treated for
five years to prevent one stroke, 29 patients (95 percent
confidence interval, 18 to 75) to prevent one major
cardiovascular event, and 32 patients (95 percent
confidence interval, 22 to 59) to avoid one revascularization
procedure.
So how important are statins in Pakistani
stroke patients?
After Diabetes and Hypertension, the third important
modifiable risk factor for stroke is dyslipidaemia. This trial
clearly shows that aggressive lowering of cholesterol in
patients 1-6 months from their stroke or TIA, reduces the
risk of recurrent strokes and other cardiovascular events as
well. Until this study, most of us did not consider a stroke or
a TIA an independent vascular indication for statin
administration. It is important for us to consider the cost,
risk and benefits of statin therapy in every South Asian
patient with ischaemic stroke - at the very least. 
Although the study was not powered to detect impact
in various stroke subtypes, there was an increase in the risk
of haemorrhages overall. This effect may be magnified in
South Asian setting as there is a relatively higher proportion
of patients (30 % vs. 17%) who present with intracerebral
haemorrhage. Additionally, the liver enzymes must be
carefully monitored in areas where Hepatitis is endemic.
The potential risk of recurrent haemorrhage should be
considered when one is deciding whether to administer a
statin to patients who have had a haemorrhagic stroke and
the enzymes must be monitored judiciously. 
Although the numbers needed to treat for prevention
are significant, this does not undermine the importance of
the intervention. It does however, put statin therapy lower
down in the priority list where cost is a major limitation to
treatment. We should encourage local, cheaper generic
statins to assuage some of the cost issues with therapy. 
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